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Epstein–Barr nuclear antigen 1 (EBNA1) plays a vital role in the
maintenance of the viral genome and is the only viral protein
expressed in nearly all forms of Epstein–Barr virus (EBV) latency
and EBV-associated diseases, including numerous cancer types. To
our knowledge, no specific agent against EBV genes or proteins
has been established to target EBV lytic reactivation. Here we re-
port an EBNA1- and Zn2+-responsive probe (ZRL5P4) which alone
could reactivate the EBV lytic cycle through specific disruption of
EBNA1. We have utilized the Zn2+ chelator to further interfere
with the higher order of EBNA1 self-association. The bioprobe
ZRL5P4 can respond independently to its interactions with Zn
2+
and EBNA1 with different fluorescence changes. It can selectively
enter the nuclei of EBV-positive cells and disrupt the oligomeriza-
tion and oriP-enhanced transactivation of EBNA1. ZRL5P4 can also
specifically enhance Dicer1 and PML expression, molecular events
which had been reported to occur after the depletion of EBNA1
expression. Importantly, we found that treatment with ZRL5P4
alone could reactivate EBV lytic induction by expressing the early
and late EBV lytic genes/proteins. Lytic induction is likely mediated
by disruption of EBNA1 oligomerization and the subsequent
change of Dicer1 expression. Our probe ZRL5P4 is an EBV protein-
specific agent that potently reactivates EBV from latency, leading
to the shrinkage of EBV-positive tumors, and our study also sug-
gests the association of EBNA1 oligomerization with the mainte-
nance of EBV latency.
EBV-specific lytic inducer | EBNA1-targeting agent | dual-responsive
fluorescent EBV probe
The Epstein–Barr virus (EBV) is a human herpesvirus whichinfects the vast majority (>90%) of humans worldwide and
can establish life-long persistence in the host. This virus is
causatively associated with the development and progression of
many human malignancies of lymphocyte and epithelial origin,
including Burkitt’s lymphoma, Hodgkin’s diseases, gastric carci-
noma, and nasopharyngeal carcinoma (NPC) (1). In EBV-infected
tumor cells, viral gene expression is limited to only a few latency-
associated proteins which actively contribute to tumor cell growth,
apoptosis resistance, and immune evasion (2). Under certain cir-
cumstances, the latent virus can be reactivated into its productive
lytic phase after induction of immediate early and early phases,
which will eventually result in the synthesis of new viral DNA, late
structural proteins, and secretion of mature infectious virions with
concomitant cell death.
Epstein–Barr nuclear antigen 1 (EBNA1) is the only viral protein
expressed in nearly all forms of EBV latency and its associated
cancers which plays a vital role in the maintenance of viral genome
(3). EBNA1 is also important for the transcriptional activation of
some other EBV latency genes (4). Homodimerization of EBNA1
is known to be critical for EBNA1–DNA binding and the subse-
quent functions of oriP (latent origin of replication), including viral
DNA replication and segregation, maintenance of the EBV epi-
somal genome, and transcriptional activation (5). Thus, EBNA1 not
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only serves as a potential marker for clinical imaging but also
emerges as a molecular target for the treatment of conditions
associated with EBV. Specific inhibition of EBNA1 by dominant-
negative EBNA1 mutants (6), antisense oligonucleotides (7), oriP
blocking agents, and small molecules/macromolecules (8–12) is
shown to inhibit tumor cell growth. Furthermore, our recent study
shows that the EBNA1-binding peptide P4 derived from the
EBNA1 dimeric interface is able to interfere with the homo-
dimerization of the EBNA1 monomer and suppress EBV-infected
cell growth (13–16).
To further improve the activity of the previous peptide-based
EBNA1-targeting probe L2P4, we have utilized the EBNA1 co-
factor Zn2+ and constructed a dual-responsive fluorescent probe,
ZRL5P4 (Fig. 1A), as a specific imaging and potent anticancer
agent for EBV-associated malignancies. As previous studies have
shown, Zn2+ is necessary for EBNA1 to dimerize and activate
the oriP-enhanced transcription, and the unique region 1 (UR1)
of EBNA1 contains a pair of essential cysteines which serve as
donors to chelate the Zn2+ ion. This suggests that EBNA1 con-
tains a second dimerization/oligomerization interface in its amino
terminus, besides the one located within the DNA-binding domain
(DBD) (4, 5). We therefore incorporated 1) an EBNA1 DBD-
binding peptide P4 (14), 2) a Zn
2+ chelator [amide-linked di-(2-
picolyl)amine, DPA] to chelate Zn2+ adjacent to the EBNA1
protein, and 3) a dual-responsive fluorophore (ZRL5) indepen-
dently reflecting its binding with Zn2+ and EBNA1 to construct a
probe, ZRL5P4 (Fig. 1A). P4 (YFMVF-GG-RrRK) contains the
pentapeptide P2 (YFMVF), which can occupy the first EBNA1
dimerization interface within the DBD (13, 17), and the nuclear
localization sequence (NLS) tetrapeptide-RrRK (14). This NLS
sequence can form salt bridges with the adjacent dimerization in-
terface, which further enhances the interaction (14). The chosen
Zn2+ chelator DPA upon binding with Zn2+, exhibits enhanced
red-shifted emission of the probe (18). In addition, when the pep-
tide P4 binds to EBNA1, the intramolecular charge transfer (ICT)-
enabled fluorophore produces enhanced blue-shifted emission.
Thus, the probe ZRL5P4 is able to emit 2 independent responsive
emission signals when bound to a Zn2+ ion and the EBNA1 protein
(Fig. 1B).
Here we report how the EBNA1 probe ZRL5P4 can interfere
the EBNA1 functions and inhibit EBV-positive cell and tumor
growth. Indeed, we found that Zn2+ is essential for oligomeri-
zation but not for dimerization of the full-length EBNA1 pro-
tein, and this higher form of EBNA1 structure was specifically
inhibited by ZRL5P4, but not by the old L2P4 probe. We observed
further enhanced inhibition of oriP-mediated transactivation of
EBNA1, as well as suppression of growth in EBV-positive tumor
cells by ZRL5P4. Surprisingly, we also observed the induction of
EBV lytic gene expression and the production of infectious EBV
particles when examining the mechanism of how ZRL5P4 could
inhibit tumor growth. These interesting results suggest that
ZRL5P4 can reactivate EBV from its latent phase through the
disruption of EBNA1. The strategy of targeted reactivation of
the latent viral genome and the induction of cytotoxic effects in
virus-driven tumors is known as cytolytic virus activation therapy,
and some EBV lytic inducers have recently entered phase I/II
clinical trials (2). Our dual-responsive fluorescent EBNA1 probe
ZRL5P4 represents a specific agent to disrupt the EBNA1 pro-
tein and to potently reactivate EBV from latency, leading to
tumor cell lysis and/or induction of viral proteins that can be
targeted by immune cells and antiviral agents to eliminate EBV-
infected tumor cells.
Results
Molecular Dynamics Simulations of Interactions between ZRL5P4 and
EBNA1. Before the actual synthesis, interactions between ZRL5P4
(with or without Zn2+) and EBNA1 DBD were initially deter-
mined by molecular dynamics (MD) simulations. As only the X-
ray crystal structure of the dimeric EBNA1 DBD is available, we
decided to use this partial structure of EBNA1 to check whether
the presence of the Zn2+-chelating fluorophore ZRL5 (with or
without binding to Zn2+) in ZRL5P4 would affect its P4 to bind to
an EBNA1 monomer.
Our previous P4-EBNA1 complex model (14) was included as
a starting point for a 500-ns simulation by using the flexible
peptide docking tool CABS (SI Appendix, Figs. S1 and S2) (19).
In line with our previous analysis (14), the pentapeptide YFMVF
in P4 had occupied the dimerization interface through a hydro-
phobic interaction, and the NLS tetrapeptide-RrRK formed salt
bridges with the adjacent negatively charged residues (D601,
D602, and D605), which further enhanced the interaction. Next,
3-dimensional models of ZRL5 in both Zn
2+-free and Zn2+-
coordinated scenarios were built and optimized with the mo-
lecular mechanics analysis and conformational searching tool
LowModeMD. The Zn2+-coordinated DPA chelator fragment
in the Zn2+-ZRL5 molecule superposed very well with the
crystal structure of a highly similar compound, Zn2+-ZTF (SI
Appendix, Fig. S3) (18), suggesting that these 2 configurations
converged at the global energy minimum. The various scenarios
of Zn2+-ZRL5 dissolved in different solvents were also taken
into consideration, and the Zn2+ ion formed 5 coordination
sites where a solvent molecule occupies an additional site in
Fig. 1. Chemical, fluorescent, and EBNA1-binding characteristics of the Zn2+
chelator EBNA1 probe ZRL5P4. (A) Chemical structures of L2P4 and ZRL5P4. (B)
Schematic illustration of the emission response of ZRL5P4, binding to Zn
2+
and EBNA1. (C) Representative conformations of ZRL5P4 and Zn
2+-ZRL5P4 in
the MD simulations. The calculated generalized Born (GB) and Poisson–
Boltzmann (PB) values represent the binding free energy between EBNA1
and ZRL5P4 or Zn
2+-ZRL5P4.
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DMSO (dimethyl sulfoxide)-Zn2+-ZRL5 and H2O-Zn
2+-ZRL5
(SI Appendix, Fig. S4).
The tertiary interaction models of the Zn2+-unbound and
-bound ZRL5P4 with EBNA1 (ZRL5P4-EBNA1 and Zn
2+-
ZRL5P4-EBNA1 complexes) were constructed based on the
aforementioned P4-EBNA1 DBD and ZRL5/Zn
2+-ZRL5 models
(SI Appendix, Fig. S5). The 2 models were then subjected to 200-ns
MD simulations for structure optimization and binding energy
calculations (SI Appendix, Figs. S6–S9 and Tables S1 and S2).
The final optimized models are shown in Fig. 1C (simulation 1);
both complexes were simulated twice, and the second simulation
model is shown in SI Appendix, Figs. S7, S9, and S10. Both in-
teraction models showed stable probe–protein interactions. The
hydrophobic interactions mediated by YFMVF and the salt
bridges formed by RrRK were well conserved in the ZRL5P4-
EBNA1 and the Zn2+-ZRL5P4-EBNA1 complexes, suggesting
that the Zn2+ ion and ZRL5 do not affect P4 in a ZRL5P4 mol-
ecule to bind to an EBNA1 monomer. This observation was
further supported by the calculated binding energies using
MMPBSA (Fig. 1C and SI Appendix, Fig. S10 and Table S3) (20).
Synthesis of ZRL5P4 and Design/Synthesis of the Related EBNA1
Probes. ZRL5P4 (Fig. 1A) was then synthesized, purified, and
characterized. The synthetic route is shown in SI Appendix,
Scheme S1, and the characterization processes were carried out
(SI Appendix, Figs. S12–S14). Two other related probes, ZRL5P2
and ZRL5P6, were also synthesized to validate the EBNA1-
blocking activity and to investigate the effects of the variation
in a single amino acid in the blocking peptide. ZRL5P2 was used
as a negative control, as it contains the EBNA1 binding motif
(YFMVF) but lacks the NLS (RrRk) (14), and the rest of its
structure is identical to ZRL5P4. On the other hand, ZRL5P6
contains the peptide P6 (YFIVF-GG-RrRK) which features the
pentapeptide YFIVF to target the I563 in the common variant
form of EBNA1 in various EBV strains (21). The purities of
these 3 compounds were determined by high-performance liquid
chromatography (HPLC) (SI Appendix, Fig. S11).
Dual-Responsive Emission by ZRL5P4 toward Their Binding to Zn
2+ and
EBNA1. The fluorescent spectral changes of probes when bound
to their targets are important indicators to reflect interactions
(22). The absorption spectrum of ZRL5P4 in aqueous solution
(Hepes) was first determined (SI Appendix, Fig. S15). The
emission of ZRL5P2, ZRL5P4, and ZRL5P6 was then examined in
the absence and presence of Zn2+ in aqueous solution (CH3CN/
0.05 M Hepes [pH 7.4], 50:50) (Fig. 2A and SI Appendix, Fig.
S16). Only ZRL5P4 showed a 1.3-fold emission enhancement
with a 4-nm red-shifted emission (451 to 455 nm) upon the ad-
dition of Zn2+, while the other 2 probes showed either a slightly
blue-shifted emission (ZRL5P2, 448 to 445 nm) or an unchanged
maximum emission wavelength (ZRL5P6, 438 nm). We then fo-
cused on working out the detailed kinetics of the enhanced red-
shifted emission mediated by ZRL5P4. We measured the lumi-
nescence of ZRL5P4 upon titration with various concentrations
of Zn2+ to check their binding stoichiometry. A gradual red-
shifted emission with a concomitant increase in the emission
intensity was observed, and the change ceased when 1 equivalent
Zn2+ had been added. This phenomenon indicates that ZRL5P4
and Zn2+ have a 1:1 stoichiometric ratio (Fig. 2B). In addition,
the binding selectivity of ZRL5P4 toward Zn
2+ versus other heavy
transition metal ions was measured (SI Appendix, Fig. S17).
Some of those metal ions decreased the emission of ZRL5P4 to
different levels; while some showed blue-shifted emission others
did not affect the emission. None of them showed a responsive
emission similar to the one of Zn2+.
We next performed a solvation study to determine the ICT
characteristic of each probe, as this mechanism contributes to
the responsive signal emitted by the fluorophore in our EBNA1
probes when binding to EBNA1. The ICT-mediated emission is
strongly solvent-dependent: The emission is enhanced and blue-
shifted with decreasing solvent polarity. Also, the ICT emission is
extremely sensitive to changes in the microenvironment and is
generally increased when the microenvironment becomes hy-
drophobic, that is, when ZRL5P4 is bound to the EBNA1
monomer. Thus, this system can be utilized as a protein binding
indicator (23). Emission changes of ZRL5P2, ZRL5P4, and
ZRL5P6 were then measured as a function of solvent polarity. As
can be seen in Fig. 2C and SI Appendix, Fig. S18, ZRL5P4 was
shown to have the best ICT characteristics. Although the emis-
sion of ZRL5P6 was also enhanced, no blue shift was observed,
however. ZRL5P4 was then evaluated for its binding activity to-
ward the EBNA1 DBD protein. It was found that the addition of
1.2 μM EBNA1 DBD to ZRL5P4 caused a 2.7-fold emission
enhancement, which was blue-shifted by 39 nm (466 to 427 nm)
(Fig. 2D). When the irrelevant human serum albumin (HSA) was
used as a negative control protein, the titration of HSA to
ZRL5P4 showed only a slight increase in its emission intensity
(Fig. 2E). Fig. 2E, Inset clearly shows that the binding of ZRL5P4
was highly selective for EBNA1 over HSA. In addition, the
fluorescence response of ZRL5P4 was also measured in the
presence of Zn2+ (Fig. 2F). A 2.4-fold enhancement with a 51 nm
Fig. 2. Dual-responsive emission of ZRL5P4 (2 μM; excitation 337 nm) toward
Zn2+ and EBNA1. (A) Fluorescence spectral changes of ZRL5P4 in the presence
of Zn2+ in aqueous solution (CH3CN/0.05 M Hepes [pH 7.4], 50:50). (B)
Fluorescence spectral changes of ZRL5P4 upon gradual addition of Zn
2+ in
aqueous solution (CH3CN/0.05 M Hepes [pH 7.4], 50:50). (C) Solvation study
of ZRL5P4 with a decrease of solvent polarity. Fluorescence spectral changes of
ZRL5P4 in PBS upon addition of (D) EBNA1 and (E) HSA and upon addition
of EBNA1 in the presence of (F) 1 equivalent Zn2+. (E, Inset) The selectivity of
ZRL5P4 toward EBNA1 over HSA. (F, Inset) Interaction of ZRL5P4 with EBNA1 in
the presence and absence of Zn2+. a.u., arbitrary units.
26616 | www.pnas.org/cgi/doi/10.1073/pnas.1915372116 Jiang et al.
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(477 to 426 nm) blue-shifted emission was observed, suggesting
that the presence of Zn2+ did not significantly affect ZRL5P4-
EBNA1 binding, as the same order of enhanced emission in the
absence of Zn2+ was observed (Fig. 2D). This observation was
further supported by the above MD simulation results (Fig. 1C).
Confirmation of the Interaction of ZRL5P4 with Zn
2+ by NMR Study.
To characterize the mechanism of how ZRL5P4 interacts with
Zn2+, 1H NMR titration analysis of ZRL5P4 with and without 1
equivalent Zn2+ were conducted. The amide– imidic acid
tautomer-binding mode of a similar Zn2+ chelator was adopted
to analyze if our Zn2+-chelating fluorophore ZRL5 interacts with
Zn2+ in a similar fashion in different solvents (18). We found
that the Zn2+ chelate complex is an amide tautomer in CH3CN,
whereas it is an imidic tautomer in DMSO. The 1H NMR
spectroscopy analysis of compound 5 (the precursor of ZRL5)
with/without Zn2+ in CD3CN and DMSO-d6 was conducted.
Compound 5 was used as a substitute for ZRL5P4 because the
presence of its peptide moiety will hinder an accurate
Zn2+ binding analysis. Consistent with the previous study (18),
proton 8 showed a large upfield shift from 10.93 to 9.43 parts per
million (ppm) in CD3CN but showed a down-field shift from
10.72 to 10.84 ppm in DMSO-d6 (SI Appendix, Fig. S19). These
findings have confirmed the 2 binding modes of ZRL5P4 in
MeCN and DMSO, indicating that the Zn2+-triggered amide
tautomerization can also occur for ZRL5P4 (Fig. 1B).
ZRL5P4 Selectively Prevents Oligomerization of EBNA1 and Diminishes
oriP-Enhanced Transactivation by EBNA1. After the chemical and
physical properties of ZRL5P4 were characterized, its ability to
inhibit EBNA1 dimerization/oligomerization in the absence and
presence of Zn2+ was assayed and was compared with the pre-
vious L2P4 EBNA1 probe. Zn
2+ is necessary for the UR1-
mediated self-association, and UR1 maps to the residues 64 to
89 of the amino terminus but not to the EBNA1 DBD. Thus, the
full-length EBNA1 rather than the EBNA1 DBD was used. The
Zn2+-chelating fluorophore, ZRL5, by itself was also included to
determine the role of disruption of Zn2+ alone in the EBNA1
self-association. In the absence of Zn2+, the EBNA1 dimer for-
mation was drastically prevented by L2P4 alone or in combina-
tion with ZRL5, whereas ZRL5P4 and ZRL5 had no obvious
effect on the EBNA1 dimer (Fig. 3A). Interestingly, the EBNA1
oligomer could only be formed in the presence of Zn2+, and this
oligomer was nearly completely abolished by ZRL5P4, but the
dimer was not significantly affected by this probe. Whereas L2P4
could only partially inhibit the EBNA1 dimer but had no significant
Fig. 3. ZRL5P4 inhibits EBNA1 oligomerization and transactivation and cell viability. (A) Full- length EBNA1 self-association in the absence/presence of Zn
2+ by
ZRL5/ZRL5P4/L2P4/ZRL5 + L2P4; 0.1% DMSO serves as the solvent control. Long and short exposure images of the same blot are shown for comparison of various
forms of EBNA1 self-association. Analysis of the effects of EBNA1 probes (ZRL5P4, L2P4) on the oriP-enhanced transactivation in EBV-positive (B) C666-1 and (C)
NPC43 cells. The transactivation activities were detected by the oriP-Cp-luciferase reporter. EDTA and TPEN are the known chelators of Zn2+. (D–H) Cytotoxic
activities of the EBNA1 probes ZRL5P2, ZRL5P4, and ZRL5P6 in the EBV-positive and -negative cell lines. Cytotoxicity of EBV-positive (D) NPC43 cells, (E) C666-1
cells, and (F) Raji cells (concentrations 1, 3, 5, 10, 15, and 20 μM) and EBV-negative (G) HK-1 cells and (H) HONE-1 cells (concentrations 1, 5, 10, 20, 50, and
100 μM) were measured by the MTT assay. Cells were treated with different probes and then incubated for 5 d to test their cytotoxicity (half of the medium
was replaced every 4 d with fresh medium containing the appropriate concentration of the probes). Data are expressed as the means ± SD.
Jiang et al. PNAS | December 26, 2019 | vol. 116 | no. 52 | 26617
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effect on the oligomer in the presence of Zn2+, ZRL5 had no ob-
vious influence on both dimer and oligomer (Fig. 3A). These results
indicate that the presence of Zn2+ can reinforce the dimerization
and lead to oligomerization, and the exhaustion of Zn2+ ion in close
proximity to EBNA1 by ZRL5P4 can eradicate the oligomerization.
On the other hand, the combination treatment of L2P4 with ZRL5
could completely inhibit both dimer and oligomer formation. It is
likely that these 2 compounds can work synergistically to eradicate
the various forms of self-association of EBNA1. We then compared
the effects of ZRL5P4 and L2P4 on the oriP-enhanced trans-
activation and investigated the role of the Zn2+ chelator in ZRL5P4
in disrupting the EBNA1 function. EBV-positive NPC C666-1 and
NPC43 cells were exposed to ZRL5P4 and L2P4, and the luciferase
reporter assay was performed. Two chelators known to have high
specificity for Zn2+, ethylenediaminetetraacetic acid (EDTA) and
N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN), were
included as positive control agents. ZRL5P4 diminished the trans-
activation by EBNA1 in both C666-1 and NPC43 cell lines, and
L2P4 could be only effective in C666-1 (Fig. 3 B and C). The effect
of ZRL5P4 was found to be more potent than L2P4 in both C666-1
(P = 0.02837) and NPC43 cell lines (P = 0.00007) (Fig. 3 B and C).
These data suggest that the addition of Zn2+ is more effective in
reducing the EBNA1 transactivation activity, and disrupting the
EBNA1 oligomer seems more critical than its dimer.
ZRL5P4 Reduces the Viability of EBV-Positive Cells and Localizes to
Their Nuclei. We next measured the cell viability of a panel of
EBV-positive (NPC43 and C666-1 NPC cells and Raji lymphoma
cells) and EBV-negative (HK-1 and HONE-1 NPC cells) cells
treated with ZRL5P2, ZRL5P4, and ZRL5P4 (Fig. 3 D–H). Both
C666-1 and NPC43 have Y561F“M”VF565, while Raji has
Y561F“I”VF565 at the DBD. Obvious cytotoxicity was observed
in these 3 EBV-positive cells, even when treated with low dos-
ages of 1 to 20 μM probes. ZRL5P4 and ZRL5P6 displayed very
similar growth-inhibitory effects, with ZRL5P2 (lacking the NLS)
being the least efficient one. In contrast, treatments with ZRL5P4
and ZRL5P6 in EBV-negative cells only showed <50% inhibition
at a much higher dose (100 μM) (Fig. 3 G and H), indicating that
Fig. 4. Nuclear localization of the EBNA1 probes and their in vivo antitumor activities. (A–C) Two-photon fluorescence imaging of ZRL5P2, ZRL5P4, and ZRL5P6
in living EBV-positive (A) NPC43 cells and (B) C666-1 cells and EBV-negative (C) HONE-1 cells. ZRL5Pn, signal emitted from the respective EBNA1 probe. DRAQ5
is a fluorescent dye used to label the cell nuclei of the living cells as indicated. (D) In vitro emission spectra (from confocal microscopy) of ZRL5P2, ZRL5P4, and
ZRL5P6 in the nucleus of EBV-positive NPC43 and C666-1 and EBV-negative HONE-1 cells. Emission intensity was much greater for ZRL5P4 and ZRL5P6 in EBV-
positive cells. (E) In vivo antitumor activity of ZRL5P2, ZRL5P4, and ZRL5P4. Mice transplanted with C666-1–derived tumors were treated twice weekly with 4 μg
per injection of the probes for 18 d. Throughout the treatment period, tumor volumes were measured. At the experimental endpoint, tumors were excised.
Data are expressed as the means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 vs. control (0.1% DMSO). (Scale bars, 10 mm.) (F) Representative photographs of
tumors. (G) Representative H&E staining images of tumor sections derived from the above in vivo animal study. Cell necrosis (acellular areas indicated by
asterisk) was observed in the tumor nodules treated with ZRL5P4 and ZRL5P6. T, adjacent area with tumor cells. Magnification, 400×. (Scale bars, 20 μm.) (H)
Response of plasma EBV DNA levels in mice transplanted with C666-1 cells after the treatment of ZRL5P4. The circulating EBV DNA level of each mouse (DMSO
#1, #2; ZRL5P4 #1, #2) is shown.
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the inhibitory activities are EBV-specific. When compared to the
previous cytotoxicity study of L2P4 (median infectious dose;
23 μM in NPC43, 27 μM in C666-1, and 27 μM in Raji cells),
ZRL5P4 is likely to be more potent, suggesting that the exploi-
tation of the Zn2+ chelator enhances the cytotoxic activity, re-
gardless of epithelial or lymphoid origin.
To show that entry into the nuclei is essential for the EBNA1
probes to inhibit tumor cell viability, subcellular localization of
ZRL5P2, ZRL5P4, and ZRL5P6 were evaluated in both EBV-
positive (C666-1 and NPC43) and EBV-negative (HONE-1)
cell lines, using 2-photon excitation microscopy (λex: 700 nm).
After incubation for 3 h, the fluorescence signals were collected
in the blue channel. ZRL5P4 and ZRL5P6 were primarily located in
the nuclei of EBV-positive cells (Fig. 4 A, B, and D) and this is
in contrast to the imaging results of L2P4 we previously reported,
which showed that the majority of L2P4 was localized to the cy-
toplasm, and only a small portion was found in the nuclei (14).
On the other hand, ZRL5P2 was only found in the cytoplasm
(Fig. 4 A, B, and D) and all 3 probes showed no nuclear locali-
zation in EBV-negative cells (Fig. 4 C and D). The EBNA1 ex-
pression detected by Western blot in these 3 cell lines correlates
quite well with the signal intensities reflected by ZRL5P4 (SI
Appendix, Fig. S20A). The cellular uptake of the new and old
EBNA1 probes by EBV-positive cells was also compared and it
was found that there the uptake of L2P4 was faster than ZRL5P4
into their nuclei; however, L2P4 also accumulated in the cyto-
plasm (SI Appendix, Fig. S20B). The inclusion of a Zn2+ chelator
seems to decrease the uptake rate and increase the specificity of
ZRL5P4. Taken together, all these imaging results indicated that
the presence of both the Zn2+ chelator and NLS is critical for
more specific nuclear localization of the new EBNA1 probes to
selectively stain the EBV-positive cells.
ZRL5P4 Inhibits the Growth of EBV-Positive Tumors in BALB/c Nude
Mice. The in vivo effects of the 3 EBNA1 probes in the C666-1
xenograft were then examined. Treatment with ZRL5P2,
ZRL5P4, and ZRL5P6 did not cause any significant changes in
body or organ weights when compared to vehicle control (SI
Appendix, Figs. S21 and S22), indicating that the 3 probes did not
exhibit a toxic effect in vivo. Tumor growth was significantly
inhibited by treatment with ZRL5P4 and ZRL5P6. Both the av-
erage tumor volume and tumor weight of mice treated with
ZRL5P4 or ZRL5P6 was significantly decreased, compared to the
control (Fig. 4 E and F and SI Appendix, Fig. S23). There was no
significant difference in either tumor volume or tumor weight
when comparing the effects of ZRL5P4 and ZRL5P6. ZRL5P2
without NLS, however, did not significantly affect tumor growth.
For the control HeLa xenograft, there was no significant dif-
ference in either tumor volume or tumor weight between the
control mice and those treated with the probes (SI Appendix, Fig.
S24). When the tumor sections were stained with hematoxylin/
eosin (H&E) to examine the tissue morphology, we found that
cell necrosis was much more frequently observed in the tumor
tissues with the treatments of ZRL5P4 or ZRL5P6 than with the
ZRL5P2 and the solvent control (Fig. 4G). The cell death could
be due to the cytotoxic activities of ZRL5P4 and ZRL5P6 observed
in the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] assay for C666-1 cells (Fig. 3E), and that can also ex-
plain why the tumors shrank after these treatments. When per-
forming an independent set of in vivo experiments with transplanted
C666-1–derived tumors, the plasma EBV DNA dramatically drop-
ped from ∼350,000 and ∼67,000 to ∼3,900 and ∼4,400 copies after
treatment with ZRL5P4 (Fig. 4H). This circulating EBV DNA load
was directly proportional to the viable cell areas in the tumors and
inversely associated with body weight (SI Appendix, Fig. S25).
Hence, the plasma EBV DNA is likely a biomarker for predicting
the effectiveness of ZRL5P4.
Reactivation of the EBV Lytic Cycle by ZRL5P4. Interestingly, when
tumor sections of Fig. 4G were analyzed with immunohisto-
chemistry (IHC), the EBV immediate early, early, and late lytic
proteins, Zta, BMRF1, and VCA-p18, were mainly detected in
the tumors injected with ZRL5P4 (Fig. 5A). Nuclear and cyto-
plasmic staining of Zta, BMRF1, and VCA-p18 was observed in
these tumor tissues. After treatment with ZRL5P4, ∼10 and 15%
tumor areas were positive for Zta and BMRF1, respectively, and
more than 80% was VCA-p18 positive. On the other hand, only
negative staining was detected in the solvent control, and 0 to 2%
was observed in ZRL5P2 for these 3 lytic proteins.
Furthermore, other EBV-infected cell lines, NPC43 and HONE-
1-EBV (the recombinant EBV-containing HONE-1), were in-
cluded for the lytic phase analysis. The protein expression of the
immediate early, early, and late lytic genes, Zta, BMRF1, gp350/
220, and VCA-p18, was studied in NPC43, HONE-1-EBV, and
C666-1 cell lines in response to 10 μM ZRL5P2 and ZRL5P4.
Immunofluorescence (IF) staining was performed, and the con-
ventional chemical inducer tetradecanoyl phorbol acetate (TPA)
(20 ng/mL) with sodium butyrate (3 mM) (TPA/NaB) (2) was
also included as a positive control. The positively stained cells for
all 4 proteins were more frequently observed in ZRL5P4, and the
response to ZRL5P2 was similar to that of the solvent control in
HONE-1-EBV cells (Fig. 5B). Although the fold changes of the
4 lytic proteins in response to TPA/NaB were generally higher
than ZRL5P4, the increased levels of the 2 late proteins gp350/
220 and VCA-p18 were not statistically significant (SI Appendix,
Fig. S26). A similar observation of lytic protein induction was
obtained in the other 2 EBV-positive cell lines (SI Appendix,
Figs. S27 and S28A).
The IF results in NPC43 and C666-1 cells were validated by
Western blot analysis, which showed that the expression levels of
a number of lytic proteins were dramatically induced by ZRL5P4
(Fig. 5C and SI Appendix, Fig. S28B). Although the expression of
Rta and BMRF1 was also induced by ZRL5P2 in NPC43 cells,
the increased levels of expression were much weaker than those
of ZRL5P4 and the gp350/220 levels were similar to the solvent
control. As some histone modifiers such as TPA/NaB can induce
EBV lytic reactivation, we examined the effects of ZRL5P4 on
the acetylation of histone H3 in 2 NPC cells lines. Our agent had
no significant effect on both cell lines (Fig. 5C and SI Appendix,
Fig. S28B), and it seems that histone modification might not be
directly related to EBV reactivation induced by ZRL5P4.
We then compared the effects of our new ZRL5P4 versus the
old L2P4 probes on the EBV lytic induction. The gene expression
of EBV lytic genes including Zta, Rta, BMRF1, and VCA-p18,
was studied in 3 EBV-positive cell lines (NPC43, HONE-1-EBV,
and C666-1) in response to 10 μM ZRL5P2, ZRL5P4, or L2P4.
The gene expression was quantified by the accurate qRT-PCR
analysis. The expression of all 4 lytic genes was strikingly induced
by ZRL5P4, whereas their expression in response to ZRL5P2 was
similar to that of the solvent control (Fig. 5D). When compared
with ZRL5P4, L2P4 could only induce the 4 lytic genes with much
lower levels in NPC43 and C666-1 cells, and in HONE-1-EBV
cells the changes of these genes were either comparable to or
lower than the negative control ZRL5P2. As can be seen, the Zn
2+
chelator in ZRL5P4 is critical in initiation of EBV reactivation.
In order to verify if the EBV particles with infectious prop-
erties could actually be generated by ZRL5P4, HONE-1-EBV
cells were used. The presence of the virions was detected by
infecting Raji cells (an established B cell line), because the
recombinant EBV genome in HONE-1-EBV encodes a green
fluorescence protein (GFP), and the GFP-expressing Raji cells
reflect the production of virions by the HONE-1-EBV cells. As
can be seen, 10 μM ZRL5P4 could lead to the production of vi-
rions and which was 10.4-fold more than the DMSO control (P =
0.009) and was ∼4-fold more than the NLS-null version ZRL5P2
(P = 0.006) (Fig. 6 A and B). Although the viral titer of ZRL5P2
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was 2.6-fold higher than the solvent control, the difference was
not significant (P = 0.06). Taken together, the entry of ZRL5P4
into the nuclei of EBV-infected cells can induce the reactivation
of EBV, which might mediate the shrinkage of the transplanted
C666-1 tumors (Fig. 4 E–G).
To study the underlying mechanism(s) of how ZRL5P4 induces
EBV lytic induction, the change in expression of Dicer and PML
were examined, as previous studies indicate that these 2 proteins
are associated with EBNA1-associated lytic induction (24, 25).
The in situ protein expression of both Dicer1 and PML was
consistently up-regulated in 2 NPC cell lines in response to
ZRL5P4 (Fig. 6C and SI Appendix, Fig. S29A). The increased
protein expression of Dicer1 and PML was validated by Western
blot (SI Appendix, Fig. S29B). To show the specific induction of
these 2 proteins by ZRL5P4, the expression was checked in the
EBV-negative HONE-1 cells, and there was no induction of
Dicer1 or PML in the ZRL5P4-treated cells (SI Appendix, Fig.
S30A). Zta protein expression and cell viability were examined in
both ZRL5P4-treated HONE-1 and HONE-1-EBV, to show that
ZRL5P4 only had lytic-inducing and antitumor activities in the
EBV-positive cells (SI Appendix, Fig. S30 A–C). Thus, the in-
duction of Dicer1 and PML by ZRL5P4 is EBV-specific. To
further demonstrate whether the lytic induction is mediated by
Dicer1 and/or PML, we depleted their expression in EBV-
positive cells and examined the expression of the key lytic pro-
tein Zta in response to ZRL5P4. When the expression of Dicer1
was depleted (SI Appendix, Figs. S29B and S31A), the ZRL5P4-
induced Zta expression was almost completely attenuated in 2
EBV-positive cell lines (Fig. 6D), whereas the knockdown of PML
itself had led to the induction of Zta expression in NPC43 cells,
and ZRL5P4 could further enhance the Zta expression (SI Ap-
pendix, Fig. S31B). As can be seen, Dicer1 is likely a mediator
which can be induced by ZRL5P4 to initiate the EBV reactivation.
Discussion
EBNA1 is known as a dimeric viral protein encoded by EBV; our
previous work has confirmed P4 (CAhxYFMVFGGRrRK) is a
physical blocker to hamper EBNA1 dimerization, and hence
Fig. 5. EBV lytic induction analysis of EBV-positive tumors and cells in response to the EBNA1 probes. (A) IHC analysis of lytic proteins Zta, BMRF1, and VCA-
p18 in the transplanted C666-1–derived tumor tissues as described in Fig. 4 E–G. Representative results are shown. Nuclear and cytoplasmic staining of Zta,
BMRF1, and VCA-p18 are observed in response to ZRL5P4. Insets (in the red boxes) are the enlarged images to indicate the cellular localization of the 3
proteins. Negative control staining images are included for the mouse antibodies (mAb) against Zta and BMRF1 and for the rat antibody (rAb) against VCA-
p18. Magnification, 400×. (Scale bars, 20 μm.) (B) Representative images of immunofluorescent analysis of EBV lytic proteins, Zta, BMRF1, gp350/220, and VCA-
p18 in HONE-1-EBV cells in response to 10 μM ZRL5P2 or ZRL5P4. TPA/NaB (20 ng/mL TPA, 3 mM NaB) serves as a positive control of lytic induction. The presence
of these 4 lytic proteins is indicated by red signals. The nuclei were stained with DAPI. (Scale bars, 50 μm.) (C) Western blot analysis of Rta, BMRF1, and gp350/
220 EBV lytic proteins in NPC43 cells cultured with or without 10 μM ZRL5P2 and ZRL5P4 for 7 d. Acetylated histone H3 (Ac-Histone H3) was also detected.
β-actin serves as the loading control. (D) Gene expression analysis of EBV lytic genes, Zta, Rta, BMRF1, and VCA-p18 in NPC43, C666-1, and HONE-1-EBV cells
cultured with or without 10 μM ZRL5P2, ZRL5P4, and L2P4, for 7 (NPC43 cells), 3 (C666-1 cells), or 5 (HONE-1-EBV) d. The gene expression was analyzed by qRT-
PCR. The fold change of relative gene expression after each treatment was compared with the solvent control (DMSO). Data are expressed as the means ± CI.
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inhibit the functions of EBNA1 as well as the growth of EBV-
positive cells. Interestingly, Zn2+ was also recently reported as a
cofactor of EBNA1 self-association; it mediates interactions of
the UR1 region between 2 EBNA1 monomers through the for-
mation of “zinc finger” structure. We thereby constructed a
probe, ZRL5P4, by taking advantages of its Zn
2+-binding prop-
erty. Unexpectedly, the Zn2+ chelator acts in close proximity to
P4 to mainly disrupt the oligomerization rather than the di-
merization of EBNA1 (Fig. 3A). Interestingly, the formation of
EBNA1 oligomer was only observed in the presence of Zn2+ and
could also stabilize the dimeric EBNA1. These results are in
concordance with the previous studies that Zn2+ is required for
self-association of EBNA1 at the UR1 domain where the
Zn2+ coordination between 2 EBNA1 monomers occurs (4). The
“self-association” can represent the dimer formation from 2
homomonomers of EBNA1, as well as the formation of higher-
order EBNA1 complexes. This hypothesis is supported by the
simulation model suggested by Hussain et al. (26) that a Zn2+ ion
links 2 EBNA1 dimers to form an oligomer to bind to DNA. This
EBNA1 complex structure could possibly represent a hexameric
ring, as previously suggested (27). As the UR1 domain was
reported to be essential for the transactivation activity of EBNA1
(4, 28), that can explain why ZRL5P4 was much more effective
than L2P4 in disrupting the oriP-mediated transcription, growth
inhibition, and lytic induction. The increased potency of ZRL5P4
on the various EBNA1 and cellular activities upon L2P4 is also
reflected by the cellular imaging for the EBV-positive cell lines
(Fig. 4). The imaging results explain that the stronger inhibi-
tion can be attributed to the nuclear localization of the probe,
where EBNA1 is primarily located, and that nuclear EBNA1 is
of critical importance for its dependent function. In vivo
administration of ZRL5P4 was demonstrated to shrink sub-
cutaneous tumors (Fig. 4). The plasma EBV DNA can act as a
biomarker for prediction of the effectiveness of treatment with
ZRL5P4 (Fig. 4H). Surprisingly, the subsequent IHC staining
indicated that the necrotic tumor tissues were likely due to the
induction of EBV lytic cycle (Figs. 4 and 5). The EBV immediate
early, early, and late lytic gene/protein expression analyses and
the in vitro Raji cell infection assay showed that ZRL5P4 can
induce the EBV lytic cycle and produce infectious EBV particles
(Figs. 5 and 6 A and B). When compared with the conventional
chemical inducer (a common histone deacetylase inhibitor), the
potency of ZRL5P4 seems not as strong as the TPA/NaB treat-
ment (Fig. 5B and SI Appendix, Fig. S26). However, the micro-
molar ZRL5P4 concentration is sufficient to induce the late lytic
proteins in a similar magnitude to the millimolar NaB treatment.
The status of histone acetylation was not significantly affected by
ZRL5P4, mechanisms other than histone modification might be
involved.
In concordance with our findings, it has been reported that the
depletion of EBNA1 gene expression by small interfering RNA
(siRNA) in the EBV-infected epithelial cell lines can activate
spontaneous lytic cycle induction, indicating that EBNA1 has a
functional role in suppressing reactivation of EBV (24). Previous
studies indicate that EBNA1 can disrupt PML and Dicer ex-
pression, and these 2 proteins are required for EBV reactivation
(24, 25). Our results show that ZRL5P4 could specifically en-
hance the expression of these 2 proteins in the EBV-positive
cells, but this was not observed in the EBV-negative cells. This
observation further strengthens the evidence for the selectivity of
Fig. 6. Production of infectious EBV particle in response to ZRL5P4. The HONE-1-EBV cell line, which expresses GFP to indicate the presence of the EBV
genome, was used. This cell line was treated with 10 μM ZRL5P2 or ZRL5P4 for 4 d, and the viral particles released in the culture medium were detected by the
Raji cell assay. The culture medium was added to Raji cells for 3 d, and GFP expression reflects the reinfection by the HONE-1–released EBV particles. (A)
Representative results are shown. The GFP signal was detected by ultraviolet light exposure, and the cell morphology was captured by phase-contrast light
microscopy and the bright-field image was merged with the GFP image. Magnification, 400×. (Scale bars, 100 μm.) (B) Relative average viral titer in response
to ZRL5P2 or ZRL5P4 was compared with the solvent control (DMSO). The Raji cell assay was performed in triplicate for each treatment. **P < 0.01, statistically
significant difference. Data are expressed as the means ± SD. (C) Representative images of immunofluorescent analysis of Dicer1 and PML in HONE-1-EBV cells
in response to 10 μM ZRL5P2 or ZRL5P4. The nuclei were counterstained with DAPI and indicated in blue. (Scale bars, 50 μm.) (D) Comparison of the number of
Zta-positive cells after treatment with ZRL5P4 in the presence versus the absence of Dicer1. HONE-1-EBV and NPC43 were included. Gene silencing of Dicer1
was achieved by siRNA transfection. Zta was detected by immunofluorescent analysis. Control siRNA (siCTL) was used as a negative control. Relative per-
centage of Zta-positive was compared against the DMSO solvent control in the siRNA control cells. *P < 0.05.
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ZRL5P4, which only functions in the presence of EBNA1. Im-
portantly, the presence of Dicer1 seems essential for the lytic
induction by ZRL5P4, while the change in PML expression levels
is also associated with the ZRL5P4-induced EBV reactivation.
Our study also suggests that the function of EBNA1 and the role
of EBV latent infection is associated with the maintenance of
tumor cell survival through suppressing lytic cycle reactivation.
Substantial advancement has been observed toward development
of novel viral-reactivating agents for induction of cytocidal ef-
fects in various EBV-associated tumor cells. This strategy has
eventually entered clinical phase I/II trials, and significant im-
provements in clinical outcome were observed in at least a
portion of the EBV-positive lymphoma patients (2). A recent
study by Messick et al. (29) has described a small molecule that
inhibits the DNA binding activity of EBNA1; this molecule can
suppress the growth of NPC and other EBV-associated tumors
but does not appear to induce the EBV lytic cycle. The lytic in-
activation could be due to mechanisms other EBNA1-DNA
binding, such as induction of Dicer1, PML, and so on, as reflec-
ted by the present study. Thus, to our knowledge, no specific lytic
cycle inducers against EBV genes or proteins have been estab-
lished. As EBNA1 is a foreign protein to the host, in theory the
elimination of EBV-associated tumor cells by ZRL5P4 warrants
absolute specificity over all other lytic inducers.
On the other hand, we initially thought that the genetic vari-
ation at the EBNA1 dimerization sequence (the amino acid 563)
could be an important factor for the design of EBNA1 probes.
ZRL5P6 was constructed to target the EBNA1 protein with an
“I” residue at the variation position. However, the results of
various biological assays show that both ZRL5P4 and ZRL5P6
were almost equally effective in all these assays, indicating that this
amino acid residue is not critical for disrupting the self-association
of the EBNA1 monomer. These findings suggest that ZRL5P4 and
ZRL5P6 should be equally potent for suppressing the EBNA1
proteins in various EBV stains.
In conclusion, we have used Zn2+ as an important cofactor for
EBNA1 function and have constructed a series of EBNA1
probes with a Zn2+ chelator and an EBNA1-binding peptide.
The Zn2+ chelator can preferentially suppress the higher-order
form of EBNA1 complex to further enhance the inhibitory ac-
tivities of our new-generation compound ZRL5P4. Importantly,
ZRL5P4 reactivates EBV lytic induction, which is associated with
the shrinkage of EBV-positive tumors in the animal model. This
study successfully targeted a single protein (EBNA1) to induce
the EBV lytic cycle. As EBNA1 is a foreign protein to the host,
in theory this strategy of elimination of EBV-associated tumor
cells warrants absolute specificity over all other lytic induction
therapies. The current lytic analysis results also suggest that the
function of EBNA1 as well as the role of EBV latent infection is
associated with the maintenance of tumor cell survival through
the suppression of the lytic cycle reactivation. Exhaustion of
Zn2+ in the microenvironment in protein molecules might rep-
resent a new strategy in designing inhibitory agents to target
pathogenic proteins in cancer development and other diseases.
Materials and Methods
General. Unless otherwise stated, all chemicals were used as purchased
without further purification. Peptides were ordered from GL Biochem
(Shanghai) Ltd. Full-length EBNA1 with N-terminal His tag was purchased
from Abcam (ab138345). The siRNAs were supplied by Thermo Fisher. Sol-
vents were dried using standard procedures. Purification of ZRL5P2, ZRL5P4,
and ZRL5P6 was performed on a Waters semipreparative HPLC system. NMR
spectra were recorded on a Bruker 400-MHz NMR spectrometer, and the
chemical shifts were referenced internally to tetramethylsilane or the cor-
responding solvent residues in parts per million; coupling constants are
reported in hertz. High-resolution mass spectra, reported as m/z, were
obtained on either a Bruker Autoflex MALDI-TOF or an Agilent 6450 UHD
Accurate-Mass Q-TOF spectrometer. UV-visible absorption spectra were
recorded on a Cary 8454 spectrometer.
Syntheses. All new compounds were characterized by 1H and 13C NMR
spectroscopy and high-resolution mass spectrometry. Characterization data
are shown in SI Appendix.
MD Simulation. All-atom unbiased MD simulations in AMBER 14 with
aff99SBildn force field were used. The system preparation and simulation
procedures were the same as those reported previously (14). In brief, a pe-
riodic boundary, cubic, TIP3 (30) explicit water box with a 20-Å buffer was
used with charge neutralized by adding Cl− ions. The system was then
minimized and equilibrated by sander using 3 stages: 1) heating from 100 to
300 K in 20 ps, 2) adjusting the solvent density to 1 g/mL in 20 ps, and 3)
equilibrating in 200 ps with NPT ensemble. A subsequent 100-ns NPT simu-
lation was performed with CUDA-accelerated PMEMD (31, 32). A 2-fs time
step and SHAKE-enabled settings were used for all of the equilibration and
production stages. A Berendsen thermostat was adopted for temperature
control at all stages.
Luminescence Measurements. Luminescent spectra were recorded on a Horiba
Fluorolog-3 spectrofluorometer equipped with a xenon lamp. Specifically,
the selectivity assay of ZRL5P4 toward Zn
2+ among many heavy metal ions
was performed in Hepes buffer (0.05 M, pH 7.4)/CH3CN (50:50) using per-
chlorate salts as the metal source [Zn(ClO4)2, Cd(ClO4)2, Cu(ClO4)2, Co(ClO4)2,
Ni(ClO4)2, Hg(ClO4)2 and Mg(ClO4)2]. The selectivity assay of ZRL5P4 toward
EBNA1 was measured in phosphate-buffered saline (PBS) buffer. Lumines-
cence titration experiments were performed by gradually increasing the
concentration of the analytes in the aqueous solution of ZRL5P4, including
Zn2+, EBNA1, and HSA; the titration was stopped when the emission change
of ZRL5P4 ceased.
Dimerization/Oligomerization Assay. Full-length EBNA1 (residues 1 to 641)
with an N-terminal His tag (ab138345; Abcam) was used in this assay. Each
0.875 μg of EBNA1 was incubated without or with 50 μM Zn2+ at room
temperature in the presence of 8 ng oriP DNA and 100 μM probe (buffer/
L2P4/ZRL5P4) for 1 h at 37 °C to allow self-association to occur. After in-
cubation, sodium dodecyl sulfate (SDS) loading buffer was added to each
system, which was then separated using denaturing SDS/polyacrylamide gel
electrophoresis, transferred onto a nitrocellulose membrane, and blotted
with an antibody against the His tag (GeneTex); the obtained protein bands
provided information of dimerization/oligomerization inhibition.
Luciferase Reporter Assay for EBNA1 oriPI-Dependent Transactivation. To study
EBNA1-dependent transactivation, the luciferase vector J988F containing the
EBV C promoter and oriPI (family of repeats) was constructed. The EBV C
promoter and oriPI (nucleotides 7447 to 11412) regions were subcloned
from the previously described plasmid pgCp(-3889)CAT (33, 34) as a HindIII
fragment into the pGL3Basic luciferase vector (Promega). Correct sequences
were ascertained by Sanger sequencing using the ABI PRISM Big Dye ter-
minator cycle sequencing kit (Applied Biosystems). EBV-positive C666-1 and
NPC43 cells were then transiently transfected with the J988F reporter plas-
mid. Cells were seeded in 12-well plates and cotransfected with the J988F
plasmid (2 μg per well) and a pRL Renilla luciferase control reporter (500 ng
per well) (Promega) using Lipofectamine 2000 (Invitrogen). After 24 h, the
cells were treated with ZRL5P4, L2P4, EDTA, or TPEN (10 μM) for another 8 h.
Cells were lysed with Passive Lysis Buffer (Promega), and the lysate was then
transferred onto a white, opaque, 96-well plate. The luciferase activities
were measured using the Dual Luciferase Reporter Assay System (Promega)
with the GloMax 96 Microplate Luminometer (Promega). The pRL Renilla
luciferase reporter was used as an internal control to normalize the trans-
fection efficiency among the samples.
Cell Culture. Six cell lines were used in this work: the EBV-negative HK-1 and
HONE-1 lines and the EBV-positive NPC43, C666-1, HONE-1-EBV, and Raji
lines. HK-1, HONE-1, HONE-1-EBV, C666-1, and Raji cells were grown in RPMI
medium 1640 supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin and streptomycin at 37 °C and 5% CO2. NPC43 cells were main-
tained in RPMI 1640 with 10% FBS and 4 μM Y27362 (inhibitor of Rho-
associated, coiled-coil-containing protein kinase; Enzo Life Sciences). C666-1,
HK-1, and HONE-1 cells were obtained from the Hong Kong NPC AoE Cell Line
Repository, NPC43 and HONE-1-EBV were supplied by S.W.T., and Raji was
supplied by ATCC. All of the cell lines were authenticated by using the
AmpFℓSTR Identifier PCR Amplification kit (Life Technologies) (SI Appendix,
Table S5) and were tested to be mycoplasma-negative by PCR.
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MTT Assay. All cells were subcultured in 96-well plates at the optimal growth
density (HK-1, 1 × 104 cells/100 μL per well; HONE-1, 8 × 103 cells/100 μL per
well; NPC43, 8 × 103 cells/100 μL per well; C666-1, 3 × 104 cells/100 μL per
well; Raji, 1 × 104 cells/100 μL per well) for 24 h. The growth medium was
then replaced by solutions of ZRL5P2, ZRL5P4, or ZRL5P6 at concentrations of
1, 5, 10, 20, 50, and 100 μM for EBV-negative cells or at concentrations of 1,
3, 5, 10, 15, and 20 μM for EBV-positive cells (for the suspensions of C666-1
and Raji cells, the 96-well plate was centrifuged at 1,000 rpm for 3 min before
each replacement/withdrawal of medium and operated with care during the
assay). After culturing for a further 5 d (half of the volume of medium was
replaced every 4 d with fresh medium containing the appropriate drug con-
centration), the cells were rinsed with PBS and then incubated with a solution
of MTT (0.5 mg/mL, 50 μL) in PBS at 37 °C for 3 h. Then, 70% of the medium
was carefully removed, DMSO (100 μL) was added, and the plate was shaken
for 30 min to solubilize the formazan produced by living cells. The optical den-
sities were measured with a dual-wavelength Labsystem Multiskan microplate
reader (Merck Eurolab) at wavelengths of 540 and 690 nm and expressed as a
percentage relative to control cells (cells without drug treatment served as the
control). Measurements were performed in triplicate and repeated twice. Cell
viability (percent) was calculated according to Eq. 1:
Viabilityð%Þ= ðODi=ODcÞ× 100%, [1]
where ODi and ODc are the optical densities of the surviving cells treated
with or without drug, respectively.
Confocal Microscopy and Costaining. Cells were incubated with ZRL5P2/ZRL5P4/
ZRL5P6 (10 μM) for 3 h and then costained with DRAQ5 (5 μM) for 30 min.
Images were acquired using a Leica TCS SP8 confocal laser-scanning micro-
scope equipped with a coherent femtosecond laser (680 to 1,050 nm), argon
laser (432, 457, and 488 nm), He-Ne laser (632 nm), ultraviolet lamp, and a
controlled CO2-content stage-top tissue culture chamber (37 °C, 2 to 7%
CO2). In vitro images of ZRL5P2/ZRL5P4/ZRL5P6 were obtained under 2-photon
excitation (λex = 700 nm), whereas images of DRAQ5 were acquired under
single-photon excitation (λex = 638 nm). The real-time live imaging was
performed with a Nikon Eclipse Ti2 confocal laser-scanning microscope.
Nude Mice Xenograft and Intratumoral Injection. C666-1 cells (8 × 106) sus-
pended in 100 μL of serum-free RPMI medium were injected into the right
flanks of 6- to 8-wk-old male BALB/c nude mice. After 21 d of inoculation,
when tumors had grown to an average volume of ∼220 mm3, mice were
assigned to treatment groups (n = 5 per group) such that the average tumor
volumes varied between groups by no more than 10%. Twice weekly, mice
received 4 μg per tumor intratumoural injections of ZRL5P2, ZRL5P4, or ZRL5P6
in 0.1% DMSO using a 29-gauge syringe. Mice that received an equivalent
volume of 0.1% DMSO alone served as controls. The treatment period lasted
for 18 d. Body weight and tumor volumes were measured twice weekly, and
tumor volumes were calculated as (length × width2)/2. At the end of the
treatment period, mice were killed and their tumors and major organs were
harvested and weighed. The investigators were blinded to treatment
grouping during the experiments and analysis of data. All animal experi-
ments were approved by the Department of Health of the Hong Kong
Government and the Animal Subjects Ethics Sub-Committee of Hong Kong
Polytechnic University. No power analyses were used to calculate the sample
size for the animal studies.
Quantitative Analysis of Cell-Free Plasma EBV DNA. The plasma EBV DNA was
detected as previously described (35). In brief, the plasma DNA was extracted
using the QIAamp DNA Blood mini kit. The PCR primers and probe and the
reaction condition strictly followed the same study. The EBV-positive cell line
Namalwa was used as a standard, and the EBV copy number was calculated.
qPCR Gene Expression Analysis. qPCR was performed as reported (36). The
primers used in this study were described in a previous publication (36, 37).
IF Staining. IF staining was performed as previously described (36). Primary
antibodies against Zta were supplied from Argene (Verniolle). Antibodies
against BMRF1, gp350/220, and VCA-p18 were generated by J.M.M. These
antibodies were produced and characterized as previously described (38–40).
The Dicer1 and PML antibodies were supplied by Abcam and Bethyl Labo-
ratories, respectively. Images were captured by the Eclipse Ti System (Nikon).
Western Blot Analysis. Western blot analysis of Zta, Rta, BMRF1, and gp350/
220 was performed as reported (41). The Rta antibody was supplied from
Argene (Verniolle) and the β-actin antibody for loading control was supplied
from Cell Signaling Technology. Antibodies against Zta, BMRF1, gp350/220,
Dicer1, and PML were the ones used for IF staining. A 1:400 dilution of the
primary antibodies was used.
Preparation of Formalin-Fixed, Paraffin-Embedded Tumor Tissues, H&E Stain,
and IHC. The transplanted tumor tissues were fixed with formalin and em-
bedded in paraffin accordingly to the general practice. The histologic sections
were prepared and stained with H&E. The lytic protein markers were stained
with IHC antibodies against Zta and BMRF1. The Zta and the BMRF1 anti-
body were the ones used for Western blot analysis. The slides were in-
cubated with the primary antibodies (1:100 dilution) for IHC as previously
described (41).
EBV Infection Assay. The HONE-1-EBV cell line was used to produce the in-
fectious EBV particles for the lytic analysis; this cell line was generated by
introducing a GFP open reading frame in the recombinant Akata EBV ge-
nome into the EBV-negative NPC cell line HONE-1 (42). The procedures of
production of viral particles and quantitation of virus titers were followed as
previously described (43, 44). In brief, after incubation with various EBNA1
probes for 96 h, the supernatants were filtered through 0.45-μm-pore filters
and the viral particles were enriched by centrifugation at 20,000 × g for 2 h.
The relative virus titers were determined by the Raji cell assay and were
quantified with the GFP expression of Raji cells infected with the virus stocks
to be analyzed. The Raji cells (1 × 105) were incubated in 96-well plates and
cultivated for 3 d at 37 °C to allow the expression of GFP. The number of
GFP-positive cells was counted by ultraviolet microscopy.
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